Astellas to Present New Long-Term Survival Data for Cancer Therapies at ASCO 2025
Key Insights
Astellas will showcase 16 abstracts at the 2025 ASCO Annual Meeting, including two oral presentations highlighting long-term survival data for its oncology portfolio.
New post-hoc analyses will feature five-year overall survival data for XTANDI (enzalutamide) in metastatic hormone-sensitive prostate cancer (search) and exploratory analyses for PADCEV (enfortumab vedotin) in urothelial cancer (search).
The presentations underscore Astellas' commitment to delivering meaningful clinical outcomes for patients with advanced prostate and bladder cancers through innovative treatment approaches.
Astellas Pharma Inc. will present 16 abstracts featuring new clinical data across its approved cancer therapies at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3. The presentations will highlight Astellas' continued focus on improving long-term patient outcomes in oncology.
The research includes significant new post hoc analyses of long-term overall survival (OS) data for XTANDI (enzalutamide) and two analyses for PADCEV (enfortumab vedotin), demonstrating the ongoing clinical benefits of these standard-of-care medicines in advanced cancers.
Key Presentations Focusing on Overall Survival
XTANDI (Enzalutamide) in Prostate Cancer
A major highlight will be the oral presentation of the ARCHES five-year follow-up OS analysis of enzalutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (search) (mHSPC). This long-term data is crucial for understanding the sustained benefits of the treatment regimen.
Additionally, eight-year data assessing outcomes of enzalutamide versus non-steroidal anti-androgen (NSAA) therapy in mHSPC will be presented from the independent, investigator-sponsored ENZAMET trial led by the Australian and New Zealand Urogenital and Prostate Cancer (search) Trials Group (ANZUP).
"Long-term overall survival is the gold standard endpoint in cancer research," said Shontelle Dodson, Executive Vice President and Head of Medical Affairs at Astellas. "New post hoc analysis data from the ARCHES enzalutamide trial demonstrates our mission to help patients live longer, healthier lives."
PADCEV (Enfortumab Vedotin) in Urothelial Cancer
Two analyses from the phase 3 EV-302 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC) will be presented:
- An oral presentation featuring an exploratory analysis of responders
- A poster presentation highlighting long-term subgroup analysis
These analyses will provide valuable insights into the efficacy of this combination therapy in different patient populations.
Additional Research in Bladder Cancer
A systematic review and meta-analysis of surrogate endpoints in muscle-invasive bladder cancer (search) trials will be featured in a poster presentation, contributing to the broader understanding of clinical trial design and endpoints in this disease area.
Advancing Cancer Care Through Innovation
"At Astellas, we are dedicated to transforming cancer care through innovative treatment approaches," said Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development at Astellas. "The data we will present at ASCO this year, including new long-term follow-up data for advanced prostate and bladder cancers, reflect the pioneering role we continue to play in delivering outcomes that matter to patients."
The company's presentations will also include data on zolbetuximab and gilteritinib, as well as updates from its pipeline programs, demonstrating Astellas' comprehensive approach to oncology research and development.
Collaborative Research Efforts
Astellas' research presentations highlight the importance of collaboration in advancing cancer care. The company maintains strategic partnerships with other pharmaceutical companies, including:
- A clinical collaboration with Pfizer and Merck to evaluate the combination of PADCEV (enfortumab vedotin) and Merck's KEYTRUDA (pembrolizumab) in patients with previously untreated metastatic urothelial cancer
- A commercial agreement with Pfizer for the joint development and commercialization of XTANDI (enzalutamide)
These collaborations enable more comprehensive research and potentially faster advancement of new treatment options for patients with difficult-to-treat cancers.
Focus on Patient-Centered Outcomes
The emphasis on long-term overall survival data across Astellas' presentations reflects the company's commitment to endpoints that are most meaningful to patients and clinicians. By continuing to investigate the durability of treatment responses and long-term safety profiles, Astellas aims to provide healthcare providers with the information needed to make optimal treatment decisions.
"We continue to push the boundaries of cancer treatment with our growing pipeline, using novel modalities and precision medicine approaches, to benefit all eligible patients now and in the future," added Chatterjee-Kishore.
The 2025 ASCO Annual Meeting will provide an important platform for sharing these advances with the global oncology community, potentially influencing treatment guidelines and clinical practice for patients with prostate, bladder, and other cancers.